Chief Executive Officer
Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million series B round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom's assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.
Benedikt Timmerman, PhD, MBA
Deputy Chief Executive Officer
Before he co-founded the Company Genticel with Ludovic de Meeus d'Argenteuil in 2001 under the name of BT Pharma, Benedikt had acquired over ten years of international experience in life science companies. Initially, he ran the Company as sole Managing Director, and as Chairman of the Management Board from 2007 on.
Prior to founding the Company, Benedikt was Biotechnology Director at Sandos Seeds (1991-1994), Senior R&D Director at Novartis Seeds from 1994 to 2000, member of the European Executive Committee of the same group from 1995 to 2000 and member of the "licenses and acquisitions" group at Novartis Agribusiness from 1997 to 2000.
Benedikt obtained a doctorate in science at the University of Ghent in Belgium in 1986 as well as MBA at INSEAD in France in 1991.
Philippe Wiesel, MD
Executive Vice President and Chief Medical Officer
Philippe joined Genkyotex in 2010 and is responsible for all clinical development activities. Previously, Philippe founded Genexion, a clinical development company focused on developing early stage clinical assets with emerging biotech companies and European venture capital firms. Prior to founding Genexion, Philippe was Medical Director at Serono's Swiss and US offices, where he was involved with the global development of several biologics and small molecules. In particular, he led the late-stage clinical development of Raptiva, achieving the first marketing authorization in Europe for a biological therapy targeting psoriasis. Philippe also led the development of Onercept in psoriasis and managed clinical development programs for beta interferon, interleukin-18 binding protein, and atacicept. Prior to joining the biotech industry, he conducted basic research for over five years in the laboratories of Professor Edgar Haber at Harvard Medical School, and Professor Hans Brunner at the Division of Hypertension in Lausanne. Philippe holds a MD degree from the University of Lausanne.
Director of Finance and Administration
Alexandre joined Genkyotex in April 2012. After management studies in the UK (Middlesex University) and in France (CESEM, Reims Management School) he started his career in 2001 in Paris as Financial Auditor with KMPG. He moved to Switzerland in 2004 first for Intrawest, a real estate company, and then oriented his career to the pharma/biotech industry with diverse experiences in Finance with Novartis from 2007-2010 and Alexion from 2010 to 2012.